Targeted therapy for small cell lung cancer

Targeted Oncology

Volumn 2, Issue 2, 2007, Pages 89-97

  Ganti, Apar Kishor ^a,b   Panwalkar, Amit W ^a  

^a Division of Hematology Oncology   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Angiogenesis; Apoptosis; Small cell lung cancer; Targeted therapy; Vaccines

Indexed keywords

EID: 34147181551     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-007-0045-6     Document Type: Review

References (87)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106-130
2. Adjei AA, Marks RS, Bonner JA (1999) Current guidelines for the management of small cell lung cancer. Mayo Clin Proc 74:809-816
3. Travis WD (2002) Pathology of lung cancer. Clin Chest Med 23:65-81, viii
4. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710-1717
5. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO et al (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291
6. Janne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA, Johnson BE (2002) Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95:1528-1538
7. Chute JP, Chen T, Feigal E, Simon R, Johnson BE (1999) Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 17:1794-1801
8. Reber L, Da Silva CA, Frossard N (2006) Stem cell factor and its receptor c-kit as targets for inflammatory diseases. Eur J Pharmacol 533:327-340
9. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H, Takahashi T (1991) Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6:2291-2296
10. Rygaard K, Nakamura T, Spang-Thomsen M (1993) Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 67:37-46
11. Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K, Ariyoshi Y, Takahashi T (1991) Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 51:2416-2419
12. Potti A, Moazzam N, Ramar K, Hanekom DS, Kargas S, Koch M (2003) CD117 (c-kit) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 14:894-897
13. Potti A, Ganti AK, Tuchman SA, Sholes K, Langness E, Koka V, Koch M (2005) HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive-stage small cell lung carcinoma (ESSCLC). J Carcinog 4:8
14. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T (2003) Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9:5880-5887
15. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM, Jr., Morton RF, Schild SE, Jett JR, Adjei AA (2005) A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 16:1811-1816
16. Schneider BJ, Gadgeel S, Ramnath N, Worden FP, Wozniak A, Ruckdeschel J, Kalemkerian GP (2006) Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC). J Clin Oncol (Meeting Abstracts) 24:17089
17. Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703
18. Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K (2003) Lack of c-kit exon 11 activating mutations in c-KIT/CD117- positive SCLC tumour specimens. Eur J Cancer 39:793-799
19. Tudor G, Aguilera A, Halverson DO, Laing ND, Sausville EA (2000) Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ 7:574-586
20. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U (1997) Induction of apoptosis in smallcell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89:1027-1036
21. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y (1994) Expression of Bcl-2 in small cell lung carcinoma cells. Cancer Res 54:6-8
22. Reed JC, Stein C, Subasinghe C, Haldar S, Croce CM, Yum S, Cohen J (1990) Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 50:6565-6570
23. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1812-1823
24. Rudin CM, Otterson GA, Mauer AM, Villalona-Calero MA, Tomek R, Prange B, George CM, Szeto L, Vokes EE (2002) A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 13:539-545
25. Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE (2004) Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22:1110-1117
26. Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541-573
27. Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd FA (1999) Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17:1802-1808
28. Brown PD, Giavazzi R (1995) Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 6:967-974
29. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B (2002) Prospective, randomized, doubleblind, placebo-controlled trial of marimastat after response to firstline chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439
30. Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CH, Terada M, Koeffler HP (1992) p53 mutations in human lung tumors. Cancer Res 52:1695-1698
31. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF et al (1992) Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749
32. D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, Johnson B, Buchhagen D, Bodner S, Phelps R et al (1992) High frequency of somatically acquired p53 mutations in smallcell lung cancer cell lines and tumors. Oncogene 7:339-346
33. Takahashi T, Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R (1991) The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6:1775-1778
34. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K, Chada S, Gabrilovich DI (2006) Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12:878-887
35. Grant SC, Kris MG, Houghton AN, Chapman PB (1999) Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 5:1319-1323
36. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'Addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C (2005) Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23:6854-6864
37. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
38. Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, Angeletti CA (2002) Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardio-thorac Surg 21:1105-1110
39. Thomas A, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, Laurent D, Dugan M, Steward W (2003) Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 30:32-38
40. Raefsky EL, Spigel DR, Greco FA, Yardley DA, Bradof JE, Woytowitz DV, Schreeder MT, Liggett WH, Zubkus JD, Petrone D, Hainsworth JD (2005) Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network. ASCO Meeting Abstracts 23:7050
41. Patton JF, Spigel DR, Greco FA, Liggett WH, Zubkus JD, Baskette M, Schreeder M, Woytowitz D, Nelson E, Hainsworth JD (2006) Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Research Network. ASCO Meeting Abstracts 24:7085
42. Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23:3243-3256
43. Blackhall FH, Shepherd FA (2004) Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer. Hematol Oncol Clin North Am 18:1121-1141, ix
44. Mattson K, Niiranen A, Pyrhonen S, Holsti LR, Holsti P, Kumpulainen E, Cantell K (1992) Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 28A:1387-1391
45. Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB (1994) Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 12:2321-2326
46. Kelly K, Crowley JJ, Bunn PA, Jr., Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S et al (1995) Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 13:2924-2930
47. Lebeau B, Salmoniere P, Ozenne G, Blanchon F, Leclerc P, Coetmeur D (1999) Alpha interferon as maintenance therapy for small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 18:475a
48. Cooney MM, Subbiah S, Chapman R, Ness A, Rutherford K, Warren G, Saltzman J, Mekhail T, Levitan N, Dowlati A (2005) Phase II trial of maintenance daily oral thalidomide in patients with extensive-stage small cell lung cancer (ES-SCLC) in remission. J Clin Oncol (Meeting Abstracts) 23:7166
49. Datta S, Datta MW (2006) Sonic hedgehog signaling in advanced prostate cancer. Cell Mol Life Sci 63:435-448
50. Watkins DN, Peacock CD (2004) Hedgehog signalling in foregut malignancy. Biochem Pharmacol 68:1055-1060
51. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB (2003) Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422:313-317
52. Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tumer Z, Tommerup N, Poulsen HS, Larsen LA (2006) Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer 52:281-290
53. Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91:1420-1424
54. Pandya KJ, Levy DE, Hidalgo M, Cohen RB, Lee MW, Schiller JH, Johnson DH (2005) A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report. J Clin Oncol (Meeting Abstracts) 23:7005
55. Lynch TJ Jr (1993) Immunotoxin therapy of small cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. Chest 103:436S-439S
56. Fidias P, Grossbard M, Lynch TJ Jr (2002) A phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer. Clin Lung Cancer 3:219-222
57. Fossella F, McCann J, Tolcher A, Xie H, Hwang LL, Carr C, Berg K, Fram R (2005) Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma. J Clin Oncol (Meeting Abstracts) 23:7159
58. Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H, Nakamura Y, Takahashi T (1992) Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 7:445-449
59. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85:17-26
60. Wistuba, II, Gazdar AF, Minna JD (2001) Molecular genetics of small cell lung carcinoma. Semin Oncol 28:3-13
61. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93:691-699
62. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:315-319
63. Hougaard S, Norgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M, Skovgaard Poulsen H (1999) Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines. Br J Cancer 79:1005-1011
64. Mattei MG, Riviere M, Krust A, Ingvarsson S, Vennstrom B, Islam MQ, Levan G, Kautner P, Zelent A, Chambon P et al (1991) Chromosomal assignment of retinoic acid receptor (RAR) genes in the human, mouse, and rat genomes. Genomics 10:1061-1069
65. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF (2000) Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 92:1303-1307
66. Kaelin WG Jr (1997) Recent insights into the functions of the retinoblastoma susceptibility gene product. Cancer Invest 15:243-254
67. Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, Poulsen HS, Spang-Thomsen M, Norgaard P (1997) Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci U S A 94:6933-6938
68. Sidransky D, Hollstein M (1996) Clinical implications of the p53 gene. Annu Rev Med 47:285-301
69. Yokota J, Akiyama T, Fung YK, Benedict WF, Namba Y, Hanaoka M, Wada M, Terasaki T, Shimosato Y, Sugimura T et al (1988) Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3:471-475
70. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ (1988) Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353-357
71. Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD (1983) Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306:194-196
72. Brennan J, O'Connor T, Makuch RW, Simmons AM, Russell E, Linnoila RI, Phelps RM, Gazdar AF, Ihde DC, Johnson BE (1991) myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 51:1708-1712
73. Takahashi T, Obata Y, Sekido Y, Hida T, Ueda R, Watanabe H, Ariyoshi Y, Sugiura T, Takahashi T (1989) Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res 49:2683-2688
74. Funa K, Steinholtz L, Nou E, Bergh J (1987) Increased expression of N-myc in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis. Am J Clin Pathol 88:216-220
75. Sattler M, Salgia R (2003) Molecular and cellular biology of small cell lung cancer. Semin Oncol 30:57-71
76. Newbold RF (2002) The significance of telomerase activation and cellular immortalization in human cancer. Mutagenesis 17:539-550
77. Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN (1999) Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 20:1649-1651
78. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA, Shay JW (1995) Telomerase activity in small-cell and non-small cell lung cancers. J Natl Cancer Inst 87:895-902
79. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K (2004) Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839). Oncol Rep 12:1053-1057
80. Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M (2006) EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 17:1028-1029
81. Araki J, Okamoto I, Suto R, Ichikawa Y, Sasaki J (2005) Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung Cancer 48:141-144
82. Potti A, Ganti AK, Sholes K, Langness E, Koka V, Horvarth L, Koch M (2003) Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. Clin Cancer Res 9:4872-4876
83. Potti A, Willardson J, Forseen C, Kishor Ganti A, Koch M, Hebert B, Levitt R, Mehdi SA (2002) Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 36:257-261
84. Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, Gebhard S, Beeh KM, Oesch F, Buhl R (2001) c-erbB-2 expression in smallcell lung cancer is associated with poor prognosis. Int J Cancer 92:474-479
85. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
86. de Jonge RR, Garrigue-Antar L, Vellucci VF, Reiss M (1997) Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol Res 9:89-98
87. Johl J, Chansky K, Lara PN, Davies AM, Bold R, Gandara DR (2005) The proteasome inhibitor PS-341 (bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): A SWOG (0327) phase II trial. J Clin Oncol (Meeting Abstracts) 23:7047